Questcor pharma stock

As of January 31, 2014 the Registrant had 60,583,61 8 shares of Common Stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Part III of this Annual Report incorporates by refe rence information from the definitive Proxy Stateme nt for Questcor Pharmaceuticals, Inc. s 2014 Annual Meeting of Shareholders. The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Cartt Stephen Lahue since year 2005. The trader's CIK number is 1321073.At the time of the last reporting, Cartt Stephen Lahue was the See Remarks of Asterias Biotherapeutics, Inc. . Mallinckrodt Pharmaceuticals announced today that the company expects to pay $15.4 million in a settlement with the U.S. Justice Department after allegations that Questcor Pharmaceuticals, which

Questcor Pharmaceuticals Inc. (Nasdaq: QCOR) shares surged some 30% in premarket trading Monday after announcing it has agreed to be acquired by Mallinckrodt PLC (NYSE: MNK) in a $5.6 billion cash Details: Union City, CA-based Questcor Pharmaceuticals develops and commercializes novel CNS-focused therapeutics. With 70 workers and a market cap of $366 million, the company's stock increased QCOR Dividend History & Description — Questcor Pharmaceuticals Inc. Questcor Pharmaceuticals is a biopharmaceutical company focused on the treatment of patients with autoimmune and inflammatory disorders. QUESTCOR PHARMACEUTICALS, INC. Common Stock The shareholders named on page 16 are selling up to 7,966,976 shares of our common stock. Our common stock is listed on the American Stock Exchange under the symbol "QSC." On August 14, 2003, the last sale price of our common stock as reported on the American Stock Exchange was $0.86.

This is the main Questcor Pharmaceuticals Inc stock chart and current price. You can find more details by going to one of the sections under this page such as historical data, charts, technical

QCOR Dividend History & Description — Questcor Pharmaceuticals Inc. Questcor Pharmaceuticals is a biopharmaceutical company focused on the treatment of patients with autoimmune and inflammatory disorders. QUESTCOR PHARMACEUTICALS, INC. Common Stock The shareholders named on page 16 are selling up to 7,966,976 shares of our common stock. Our common stock is listed on the American Stock Exchange under the symbol "QSC." On August 14, 2003, the last sale price of our common stock as reported on the American Stock Exchange was $0.86. Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance Why Questcor Pharmaceuticals Inc. Soared Today. Questcor is quite a unique stock in the biotech sector. Despite growing revenues by double-digits over the last few quarters, short sellers have Acthar ® Gel (repository corticotropin injection) is indicated for:. Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus; Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age On this news, Questcor's stock plummeted $24.17 per share to close at $26.35 per share on September 19, 2012, a one-day decline of 48%. Then, on September 24, 2012, Questcor announced in a Form 8-K filed with the SEC that the U.S. government had initiated an investigation into the Company's promotional practices.

This biopharma company hit its 52-week high of $54.31 on June 26 due, in part, to its efforts to launch H.P. Acthar Gel in the lucrative rheumatology space.

The Watson Generic is not a generic of Questcor's HP Acthar Gel nor any modified release form of ACTH. There are no generics of Acthar Gel that exists to our knowledge. Therefore, there should be a little, where no threat of a substitutable generic product from these previously approved discontinued products. Mallinckrodt plc and Questcor Pharmaceuticals Inc have entered into a merger agreement under which Mallinckrodt will acquire Questcor for approximately $5.6 billion. The transaction is expected to complete in Q3 2014. Patrick Spicer, head of Matheson's Corporate group, said, "We are delighted to have advised Questcor on this transaction. This biopharma company hit its 52-week high of $54.31 on June 26 due, in part, to its efforts to launch H.P. Acthar Gel in the lucrative rheumatology space. Questcor Pharmaceuticals Inc. on Monday agreed to pay $38 million to end a consolidated securities class action alleging the company lies about the efficacy of its biggest moneymaker, multiple An Irish drug maker will buy Questcor Pharmaceuticals Inc., which has a sizable East Bay operation, in a $5.6 billion cash and stock deal. Specialty drug maker Mallinckrodt plc (NYSE: MNK) of DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion.The acquisition is expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted As of January 31, 2014 the Registrant had 60,583,61 8 shares of Common Stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Part III of this Annual Report incorporates by refe rence information from the definitive Proxy Stateme nt for Questcor Pharmaceuticals, Inc. s 2014 Annual Meeting of Shareholders.

Mallinckrodt plc and Questcor Pharmaceuticals Inc have entered into a merger agreement under which Mallinckrodt will acquire Questcor for approximately $5.6 billion. The transaction is expected to complete in Q3 2014. Patrick Spicer, head of Matheson's Corporate group, said, "We are delighted to have advised Questcor on this transaction.

DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion.The acquisition is expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted As of January 31, 2014 the Registrant had 60,583,61 8 shares of Common Stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Part III of this Annual Report incorporates by refe rence information from the definitive Proxy Stateme nt for Questcor Pharmaceuticals, Inc. s 2014 Annual Meeting of Shareholders. The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Cartt Stephen Lahue since year 2005. The trader's CIK number is 1321073.At the time of the last reporting, Cartt Stephen Lahue was the See Remarks of Asterias Biotherapeutics, Inc. . Mallinckrodt Pharmaceuticals announced today that the company expects to pay $15.4 million in a settlement with the U.S. Justice Department after allegations that Questcor Pharmaceuticals, which Over the last two years, as the company's share price mainly soared, Questcor insiders have sold more than $100 million of stock. THE story of Questcor's wonder drug begins in Rochester, Minn. Value Line is initiating coverage of Questcor Pharmaceuticals (QCOR) in The Value Line Investment Survey. This biotechnology company is something of a one-trick pony, but it appears to have a really good trick.

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015 · By Adam Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today · By Jamie 

Director of Finance & Corporate Controller at Questcor Pharmaceuticals, Inc. Direct experience with pharmaceutical industry, civil engineering (service  Specialty Generics produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic-  20 Nov 2018 A pharmaceutical company proactively reached out to the Office of the Inspector voluntarily at some point after its purchase of Questcor Pharmaceuticals in 2014 Under the proposal, the company would stock the drug at 

Insider trading activities including stock purchases, stock sales, and option exercises of QSC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Questcor Pharmaceuticals Inc (symbol QSC, CIK number 891288) see the Securities and Exchange Commission (SEC) website.